Accelerate Diagnostics Stock (NASDAQ: AXDX)

Accelerate Diagnostics

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Biotech

Earnings

News

Penny Stocks

Small Cap

Markets

Trading Ideas

General

AXDX

PACB

Accelerate Diagnostics (NASDAQ: AXDX) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.70 per share a year ago. These figures are adjusted for non-recurring items.

Accelerate Diagnostics Reports Q1 Loss, Misses Revenue Estimates

Intraday Update

Movers

ABSI

ADAG

AGAE

AGFY

ALLY

ASTS

AZTR

BCDA

BFRG

CELH

CHGG

CISS

CRGE

DTSS

ESPR

EWTX

GOOG

GOOGL

IRBT

KAMN

MESA

MESO

Morgan Stanley Capital Protected Notes for S&P 500 Index

NAMS

NKTX

ORGS

PCSA

PRTG

RNAZ

SAVE

SHPH

SILK

SMCI

SOAR

VMAR

WRLD

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session.

TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share.

TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

doctor-563429

Accelerate Diagnostics shares are trading lower by 38% during Friday&#39;s session. The company priced an underwritten public offering of 6,860,659 units at $1.50 each.

Why Accelerate Diagnostics (AXDX) Stock Is Down 38%

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics Inc

Press Releases

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results

Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results.

Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results

Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results

Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial

Accelerate Diagnostics Reports Second Quarter 2024 Financial Results

Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

Biomerica

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Co-Diagnostics

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

Femasys

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

Iridex

Microbot Medical

Modular Medical

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Tech

Neuraxis

enVVeno Medical Corporation - Common Stock

enVVeno Medical

Nexalin Technology

Outset Medical

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Trinity Biotech plc - American Depositary Shares

Trinity Biotech

Venus Concept

Beyond Air

Craig-Hallum

Comments

Accelerate Diagnostics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga